WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Stock

$0.77-0.02 (-2.53%)
Updated Feb 3, 2023
IKT Price
$0.77
Fair Value Price
$1.00
Market Cap
$19.40M
52 Week Low
$0.44
52 Week High
$1.52
P/E
-1.04x
P/B
0.77x
P/S
371.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$61.82k
Earnings
-$18.82M
Gross Margin
100%
Operating Margin
-30,438.64%
Profit Margin
-30,438.9%
Debt to Equity
0.14
Operating Cash Flow
-$18M
Beta
0.87
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A

IKT Overview

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IKT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IKT ($0.77) is undervalued by 22.95% relative to our estimate of its Fair Value price of $1.00 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IKT ($0.77) is significantly undervalued by 22.95% relative to our estimate of its Fair Value price of $1.00 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IKT due diligence checks available for Premium users.

Be the first to know about important IKT news, forecast changes, insider trades & much more!

IKT News

Valuation

IKT fair value

Fair Value of IKT stock based on Discounted Cash Flow (DCF)
Price
$0.77
Fair Value
$1.00
Undervalued by
22.85%
IKT ($0.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IKT ($0.77) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IKT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IKT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.04x
Industry
10.7x
Market
15.09x

IKT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.77x
Industry
5.11x
IKT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IKT's financial health

Profit margin

Revenue
$7.3k
Net Income
-$4.5M
Profit Margin
-61,645.4%
IKT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IKT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$28.6M
Liabilities
$3.4M
Debt to equity
0.14
IKT's short-term assets ($27.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IKT's short-term assets ($27.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IKT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$5.5M
Investing
-$20.9M
Financing
$0.0
IKT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IKT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IKT$19.40M-2.53%-1.04x0.77x
ANPC$19.24M+7.26%-0.70x-40.20x
IMV$19.73M+5.26%-0.66x-4.28x
ATHE$19.01M+0.25%-1.76x0.76x
KTTA$19.83M-6.61%-2.95x0.42x

Inhibikase Therapeutics Stock FAQ

What is Inhibikase Therapeutics's quote symbol?

NASDAQ: IKT) Inhibikase Therapeutics trades on the NASDAQ under the ticker symbol IKT. Inhibikase Therapeutics stock quotes can also be displayed as NASDAQ: IKT.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.

What is the 52 week high and low for Inhibikase Therapeutics (NASDAQ: IKT)?

(NASDAQ: IKT) Inhibikase Therapeutics's 52-week high was $1.52, and its 52-week low was $0.44. It is currently -49.41% from its 52-week high and 74.77% from its 52-week low.

How much is Inhibikase Therapeutics stock worth today?

(NASDAQ: IKT) Inhibikase Therapeutics currently has 25,227,051 outstanding shares. With Inhibikase Therapeutics stock trading at $0.77 per share, the total value of Inhibikase Therapeutics stock (market capitalization) is $19.40M.

Inhibikase Therapeutics stock was originally listed at a price of $9.90 in Dec 23, 2020. If you had invested in Inhibikase Therapeutics stock at $9.90, your return over the last 2 years would have been -92.23%, for an annualized return of -72.13% (not including any dividends or dividend reinvestments).

How much is Inhibikase Therapeutics's stock price per share?

(NASDAQ: IKT) Inhibikase Therapeutics stock price per share is $0.77 today (as of Feb 3, 2023).

What is Inhibikase Therapeutics's Market Cap?

(NASDAQ: IKT) Inhibikase Therapeutics's market cap is $19.40M, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Inhibikase Therapeutics's market cap is calculated by multiplying IKT's current stock price of $0.77 by IKT's total outstanding shares of 25,227,051.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.